Recent developments in myelodysplastic syndromes

Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

(2014) Guillermo Garcia-Manero   AMERICAN JOURNAL OF HEMATOLOGY

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

(2014) Soraya Carrancio et al.   BRITISH JOURNAL OF HAEMATOLOGY

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

(2014) Aristoteles Giagounidis et al.   CANCER

Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes

(2014) David P. Steensma et al.   CANCER

Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010

(2014) Avinash G. Dinmohamed et al.   EUROPEAN JOURNAL OF CANCER

Association of the type of 5q loss with complex karyotype, clonal evolution,TP53mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome

(2014) Sarah Volkert et al.   GENES CHROMOSOMES & CANCER

Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis

(2014) H. Holstege et al.   GENOME RESEARCH

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

(2014) L. Saft et al.   HAEMATOLOGICA

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

(2014) Thomas Prebet et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

(2014) Liran I. Shlush et al.   NATURE

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

(2013) Asmita Mishra et al.   AMERICAN JOURNAL OF HEMATOLOGY

When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?

(2013) David P. Steensma et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

(2013) L. Malcovati et al.   BLOOD

STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients

(2013) A. Jerez et al.   BLOOD

The genetic basis of myelodysplasia and its clinical relevance

(2013) M. Cazzola et al.   BLOOD

How we treat lower-risk myelodysplastic syndromes

(2013) P. Fenaux et al.   BLOOD

How we treat higher-risk myelodysplastic syndromes

(2013) M. A. Sekeres et al.   BLOOD

Clinical and biological implications of driver mutations in myelodysplastic syndromes

(2013) E. Papaemmanuil et al.   BLOOD

Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes

(2013) Rami S. Komrokji et al.   BRITISH JOURNAL OF HAEMATOLOGY

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations

(2013) Mar Mallo et al.   BRITISH JOURNAL OF HAEMATOLOGY

TP53mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

(2013) Austin G. Kulasekararaj et al.   BRITISH JOURNAL OF HAEMATOLOGY

Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes

(2013) L. Senent et al.   HAEMATOLOGICA

Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis

(2013) John Koreth et al.   JOURNAL OF CLINICAL ONCOLOGY

Signal transduction inhibitors in treatment of myelodysplastic syndromes

(2013) Lohith Bachegowda et al.   Journal of Hematology & Oncology

Skewed X-inactivation patterns in ageing healthy and myelodysplastic haematopoiesis determined by a pyrosequencing based transcriptional clonality assay

(2013) Maximilian Mossner et al.   JOURNAL OF MEDICAL GENETICS

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

(2013) F Traina et al.   LEUKEMIA

NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes

(2013) D M Murphy et al.   LEUKEMIA

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

(2013) M J Walter et al.   LEUKEMIA

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

(2013) T Haferlach et al.   LEUKEMIA

P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS With del(5q) in MDS-003 and MDS-004: A retrospective analysis

(2013) M. Sekeres et al.   LEUKEMIA RESEARCH

Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry

(2013) Roger M. Lyons et al.   LEUKEMIA RESEARCH

(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

(2013) J.-A. Losman et al.   SCIENCE

Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine

(2012) Massimo Breccia et al.   ANNALS OF HEMATOLOGY

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome

(2012) Tapan M. Kadia et al.   BRITISH JOURNAL OF HAEMATOLOGY

Incidence, survival and prevalence of myeloid malignancies in Europe

(2012) O. Visser et al.   EUROPEAN JOURNAL OF CANCER

Combination strategies in myelodysplastic syndromes

(2012) Moshe C. Ornstein et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes

(2012) Hideki Tsushima et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

(2012) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

(2012) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited

(2012) Andres Jerez et al.   JOURNAL OF CLINICAL ONCOLOGY

Historical perspectives on myelodysplastic syndromes

(2012) David P. Steensma   LEUKEMIA RESEARCH

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

(2012) Lambert Busque et al.   NATURE GENETICS

Detectable clonal mosaicism and its relationship to aging and cancer

(2012) Kevin B Jacobs et al.   NATURE GENETICS

Detectable clonal mosaicism from birth to old age and its relationship to cancer

(2012) Cathy C Laurie et al.   NATURE GENETICS

TET2andDNMT3AMutations in Human T-Cell Lymphoma

(2012) Lucile Couronné et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal Architecture of Secondary Acute Myeloid Leukemia

(2012) Matthew J. Walter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors

(2012) David P. Steensma   Current Hematologic Malignancy Reports

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

(2011) K. Naqvi et al.   BLOOD

Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries

(2011) C. R. Cogle et al.   BLOOD

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

(2011) S M Luger et al.   BONE MARROW TRANSPLANTATION

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)

(2011) L. Malcovati et al.   HAEMATOLOGICA

Targeting Immune Dysregulation in Myelodysplastic Syndromes

(2011) Matthew J. Olnes   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

(2011) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

(2011) Thomas Prébet et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

(2011) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics

(2011) Masanori Mori et al.   LEUKEMIA RESEARCH

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

(2011) Timothy A Graubert et al.   NATURE GENETICS

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

(2011) Víctor Quesada et al.   NATURE GENETICS

SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts

(2011) E. Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia

(2011) Lili Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hematopoietic Growth Factors in Myelodysplastic Syndromes

(2011) David P. Steensma   SEMINARS IN ONCOLOGY

Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice

(2010) T. H.- P. Chen et al.   BLOOD

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

(2010) Mikkael A. Sekeres et al.   CANCER

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

The Epidemiology of Myelodysplastic Syndromes

(2010) Mikkael A. Sekeres   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

(2010) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions

(2010) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries

(2010) Stuart L. Goldberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99

(2010) Jakob R. Passweg et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of Myelodysplastic Syndromes in People Exposed to Ionizing Radiation: A Retrospective Cohort Study of Nagasaki Atomic Bomb Survivors

(2010) Masako Iwanaga et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidemiological data on myelodysplastic syndrome patients under 50 years in a single center of Romania

(2010) Radu Gologan   LEUKEMIA RESEARCH

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

(2010) Myunggon Ko et al.   NATURE

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

(2010) Gorica Nikoloski et al.   NATURE GENETICS

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Mutations of polycomb-associated geneASXL1in myelodysplastic syndromes and chronic myelomonocytic leukaemia

(2009) Véronique Gelsi-Boyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies

(2009) Y. Ye et al.   CANCER RESEARCH

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics

(2009) S Heinrichs et al.   LEUKEMIA

Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes

(2009) Akira Matsuda et al.   LEUKEMIA RESEARCH

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

(2009) Daniel T Starczynowski et al.   NATURE MEDICINE

Myelodysplastic Syndromes

(2009) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome

(2009) Elaine R. Mardis et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

(2009) M. Tahiliani et al.   SCIENCE

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

(2008) Hagop Kantarjian et al.   CANCER

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

(2008) G. J. Mufti et al.   HAEMATOLOGICA

Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

(2008) Mikkael A. Sekeres et al.   JNCI-Journal of the National Cancer Institute

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

(2008) Benjamin L. Ebert et al.   NATURE

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based survey

(2007) David P. Steensma et al.   LEUKEMIA RESEARCH